Panel Discussion: Integrating the Patient Voice into Rare Kidney Disease Drug Development through Trial Design, Endpoint Selection, & Treatment Delivery to Improve Therapy Adoption & Satisfaction

• Incorporating patient perspectives early in drug development to ensure therapies address meaningful outcomes such as disease progression, dialysis avoidance, and quality of life
• Incorporating patient priorities and lived experience into therapy design and development strategies
• Understanding treatment burden, delivery preferences, and risk tolerance from the patient perspective

Speakers:

Sherrita Dorsey

US Head Patient and Professional Advocacy

Amicus Therapeutics

Manish Maski

Global Medical Affairs Exec Director

Vertex Pharmaceuticals

Jennifer McKenzie

Senior Clinical Program Leader

Boehringer Ingelheim

Danielle Branch

Director, Patient Advocacy & Community Engagement

Maze Therapeutics